
In this series, expert panelists define treatment-resistant depression (TRD) and its prevalence within MDD, examining its neurobiological underpinnings, risk factors, diagnostic complexities, and quality-of-life burden. They then evaluate available treatment strategies — including glutamatergic agents and combination approaches — reviewing efficacy, safety, and practical considerations for optimizing patient outcomes.


